MicuRx(688373.SH)

Company Encyclopedia

MicuRx

688373.SH

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.

1.468 T

688373.SHMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update

BiotechnologyIndustry

Industry Ranking78/81

Industry medianC

Industry averageC

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreD
- ROE-71.15%E
- Profit Margin-133.74%E
- Gross Margin85.60%A
Growth ScoreB
- Revenue YoY15.44%B
- Net Profit YoY49.67%B
- Total Assets YoY-20.62%E
- Net Assets YoY-52.66%E
Cash ScoreB
- Cash Flow Margin86.45%C
- OCF YoY15.44%B
Operating ScoreD
- Turnover0.2D
Debt ScoreD
- Gearing Ratio73.15%D